Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel C. Capaldi is active.

Publication


Featured researches published by Daniel C. Capaldi.


Nucleosides, Nucleotides & Nucleic Acids | 1997

Synthesis of Six-Membered Nucleoside Analogs. Part 1: Pyrimidine Nucleosides Based on the 1,3-Dioxane Ring System

Daniel C. Capaldi; Alessandra Eleuteri; Qin Chen; Raymond F. Schinazi

Abstract The synthesis of pyrimidine nucleosides, cis-N-1-[(2-hydroxymethyl)-1,3-dioxan-5-yl]uracil (4) cis-N-1-[(2-hydroxymethyl)-1,3-dioxan-5-yl]thymine (5) and cis-N-1-[(2-hydroxymethyl)-1,3-dioxan-5-yl]cytosine (6) and their corresponding trans isomers is described. Compound 4 showed modest, selective activity against human immunodeficiency virus in acutely infected primary human lymphocytes.


Nucleosides, Nucleotides & Nucleic Acids | 2003

Synthesis of high quality phosphorothioate oligonucleotides as antisense drugs. Use of I-linker in the elimination of 3'-terminal phosphorothioate monoesters

Vasulinga T. Ravikumar; R. Krishna Kumar; Daniel C. Capaldi; Douglas L. Cole

Abstract Detritylation of a 5′-O-DMT-2′-deoxyadenosine moiety attached to solid support under acidic condition leads to depurination during oligonucleotide synthesis. Deprotection followed by reversed phase HPLC purification leads to desired oligonucleotide contaminated with significant levels of 3′-terminal phosphorothiaote (3′-TPT) monoester (n−1)-mer. However, it is demonstrated that attachment of dA nucleoside through its exocyclic amino group to solid support leads to substantial reduction of 3′-TPT formation thereby improving the quality of oligonucleotide synthesized.


Rapid Communications in Mass Spectrometry | 2018

Rapid oligonucleotide drug impurity determination by direct spectral comparison of ion-pair reversed-phase high-performance liquid chromatography electrospray ionization mass spectrometry data

Stilianos G. Roussis; Charlie Koch; Daniel C. Capaldi; Claus Rentel

RATIONALEnQuantitative Ion-Pair (IP)-HPLC MS methods are employed to determine the complex impurity profiles of oligonucleotide therapeutics. While impurities that co-elute with the main product are routinely monitored, the large number of early and late eluting impurities makes their individual measurements tedious and time-consuming. An improved method is needed for routine analyses.nnnMETHODSnA Combined Ranking (CR) index is developed to provide a composite value for both qualitative and quantitative impurity changes. Positive and Negative Impurity Change (PIC/NIC) indices are developed to determine the degree and direction of change. Optimized experimental conditions are determined for the characterization of trace levels of impurities. Replicate analysis, blank subtraction, and signal processing approaches are used to enhance the S/N. Dot-product and Euclidean distance equations monitor spectral changes.nnnRESULTSnSpiking experiments with individual and complex impurity mixtures show the method can distinguish among samples differing in impurity content by 0.2% wt. The method has been applied to monitor changes in impurity profile among different batches of the same oligonucleotide and changes in the same batch over time (stability analysis). The method permits rapid determination of changes in the types and amounts (increases and decreases) of impurities present.nnnCONCLUSIONSnA novel approach for the rapid determination of changes in the impurity profile of oligonucleotide therapeutics has been developed. The straightforward data treatment and the speed and simplicity of the approach make the method easy to implement and use. Possible quality control applications include drug substance and drug product stability studies, and the assessment of batch-to-batch variability.


Archive | 2004

Process for the synthesis of oligomeric compounds

Vasulinga T. Ravikumar; Muthiah Manoharan; Daniel C. Capaldi; Achim H. Krotz; Douglas L. Cole; Andrei P. Guzaev


Organic Process Research & Development | 2003

Synthesis of High-Quality Antisense Drugs. Addition of Acrylonitrile to Phosphorothioate Oligonucleotides: Adduct Characterization and Avoidance

Daniel C. Capaldi; Hans Gaus; Achim H. Krotz; Jim Arnold; Ricaldo L. Carty; Max N. Moore; Anthony N. Scozzari; Kirsten Lowery; Douglas L. Cole; Vasulinga T. Ravikumar


Journal of Organic Chemistry | 2005

Formation of Modified Cytosine Residues in the Presence of Depurinated DNA

Claus Rentel; Xiaojing Wang; Michael Batt; Christine Kurata; Jay Oliver; Hans Gaus; Achim H. Krotz; James V. McArdle; Daniel C. Capaldi


Organic Process Research & Development | 2000

Pyridinium Trifluoroacetate/N-Methylimidazole as an Efficient Activator for Oligonucleotide Synthesis via the Phosphoramidite Method

Alessandra Eleuteri; Daniel C. Capaldi; Achim H. Krotz; and Douglas L. Cole; Vasulinga T. Ravikumar


Organic Process Research & Development | 2003

Antisense Phosphorothioate Oligodeoxyribonucleotide Targeted against ICAM-1: Use of I-Linker to Eliminate 3‘-Terminal Phosphorothioate Monoester Formation

Vasulinga T. Ravikumar; R. Krishna Kumar; Daniel C. Capaldi; Brett Turney; Claus Rentel; Douglas L. Cole


ChemInform | 2008

Manufacturing and Analytical Processes for 2′-O-(2-Methoxyethyl)-modified Oligonucleotides

Daniel C. Capaldi; Anthony N. Scozzari


Archive | 2003

Oligomer phosphoramidite compositions and processes for synthesizing the same

Vasulinga T. Ravikumar; Daniel C. Capaldi; Douglas L. Cole

Collaboration


Dive into the Daniel C. Capaldi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge